Novartis' Midostaurin To Fill 30-Year Void In AML Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data presented at ASH impress clincians, hopeful for a change in standard of care.
You may also be interested in...
AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces
Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.